NASDAQ: BVS
Bioventus Inc Stock

$8.79+0.08 (+0.92%)
Updated Jun 22, 2026
BVS Price
$8.79
Fair Value Price
$25.96
Market Cap
$734.27M
52 Week Low
$5.81
52 Week High
$11.25
P/E
20.44x
P/B
3.89x
P/S
1.04x
PEG
0.57x
Dividend Yield
N/A
Revenue
$576.30M
Earnings
$28.48M
Gross Margin
68.7%
Operating Margin
8.83%
Profit Margin
4.9%
Debt to Equity
2.2
Operating Cash Flow
$103M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BVS Overview

Bioventus Inc. is a global medical technology enterprise specializing in the development and market introduction of clinical solutions that activate and bolster the body's inherent regenerative processes. The company's diverse product range is categorized into three primary segments: Firstly, pain management offerings include minimally invasive joint pain injection therapies and advanced peripheral nerve stimulation devices. Secondly, their surgical innovations feature bone graft substitutes engineered to facilitate bone fusion and growth, thereby improving results in spinal and other orthopedic procedures. This segment also comprises ultrasonic instruments employed for precise bone sculpting, tumor excision, and tissue cleansing. Thirdly, restorative therapies encompass an advanced ultrasonic system for fracture repair, along with skin allografts, specialized products for chronic wound management, and sophisticated rehabilitation devices designed to aid in the recovery of leg and hand function. Bioventus's clientele consists of medical professionals across the entire orthopedic spectrum, such as specialists in sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery. These offerings are utilized in various clinical environments, including private clinics, ambulatory surgical centers, and hospital settings. Established in 2011, Bioventus Inc. maintains its corporate headquarters in Durham, North Carolina.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BVS's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
BVS
Ranked
#1 of 93

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$38.40A
$26.22A
$138.97A
View Top Medical Device Stocks

Be the first to know about important BVS news, forecast changes, insider trades & much more!

BVS News

Overview

Due Diligence Score

Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BVS ($8.79) is undervalued by 66.14% relative to our estimate of its Fair Value price of $25.96 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BVS ($8.79) is significantly undervalued by 66.14% relative to our estimate of its Fair Value price of $25.96 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BVS ($8.79) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BVS due diligence checks available for Premium users.

Valuation

BVS fair value

Fair Value of BVS stock based on Discounted Cash Flow (DCF)

Price
$8.79
Fair Value
$25.96
Undervalued by
66.14%
BVS ($8.79) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BVS ($8.79) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BVS ($8.79) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BVS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
20.44x
Industry
19.75x
Market
7.94x
BVS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BVS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

BVS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
3.89x
Industry
2.92x
BVS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BVS price to earnings growth (PEG)

For valuing profitable companies with growth potential

BVS is good value based... subscribe to Premium to read more.
PEG Value Valuation

BVS's financial health

Profit margin

Revenue
$132.1M
Net Income
$3.1M
Profit Margin
2.4%
BVS's Earnings (EBIT) of $50.89M... subscribe to Premium to read more.
Interest Coverage Financials
BVS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$650.5M
Liabilities
$416.3M
Debt to equity
2.2
BVS's short-term assets ($249.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BVS's long-term liabilities ($268.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BVS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$8.9M
Investing
-$574.0k
Financing
-$23.1M
BVS's operating cash flow ($102.94M)... subscribe to Premium to read more.
Debt Coverage Financials

BVS vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BVSA$734.27M+0.92%20.44x3.89x
SIBNC$701.61M-0.13%-40.56x3.92x
CBLLC$689.80M+0.83%-11.15x4.90x
SSIID$672.44M-3.17%-67.20x12.33x
INMDC$837.53M-1.42%9.57x1.27x

Bioventus Stock FAQ

What is Bioventus's quote symbol?

(NASDAQ: BVS) Bioventus trades on the NASDAQ under the ticker symbol BVS. Bioventus stock quotes can also be displayed as NASDAQ: BVS.

If you're new to stock investing, here's how to buy Bioventus stock.

What is the 52 week high and low for Bioventus (NASDAQ: BVS)?

(NASDAQ: BVS) Bioventus's 52-week high was $11.25, and its 52-week low was $5.81. It is currently -21.86% from its 52-week high and 51.29% from its 52-week low.

How much is Bioventus stock worth today?

(NASDAQ: BVS) Bioventus currently has 83,534,785 outstanding shares. With Bioventus stock trading at $8.79 per share, the total value of Bioventus stock (market capitalization) is $734.27M.

Bioventus stock was originally listed at a price of $19.21 in Feb 11, 2021. If you had invested in Bioventus stock at $19.21, your return over the last 5 years would have been -54.24%, for an annualized return of -14.48% (not including any dividends or dividend reinvestments).

How much is Bioventus's stock price per share?

(NASDAQ: BVS) Bioventus stock price per share is $8.79 today (as of Jun 22, 2026).

What is Bioventus's Market Cap?

(NASDAQ: BVS) Bioventus's market cap is $734.27M, as of Jun 24, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bioventus's market cap is calculated by multiplying BVS's current stock price of $8.79 by BVS's total outstanding shares of 83,534,785.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.